NuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma
I'm PortAI, I can summarize articles.
NuCana plc announced positive Phase 2 results for NUC-7738 in combination with pembrolizumab for PD-1 inhibitor-resistant melanoma. The study, presented at the ESMO Immuno-Oncology Congress 2025, showed clinical activity with partial responses and stable disease in patients. No new safety signals were observed, supporting further enrollment and development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments